Format

Send to

Choose Destination
Pharmacol Res. 2015 Sep;99:74-81. doi: 10.1016/j.phrs.2015.05.009. Epub 2015 May 30.

Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial.

Author information

1
Research Center of Nutrition and Food Safety, The Third Military Medical University, Chongqing Key Laboratory of Nutrition and Food Safety, Chongqing 400038, PR China; Center of Preventive Treatment of Disease, Foshan Hospital of Traditional Chinese Medicine, Foshan 528000, PR China.
2
Health Care Center of Southwest Hospital (the First Affiliated Hospital of the Third Military Medical University), Chongqing 400038, PR China.
3
Research Center of Nutrition and Food Safety, The Third Military Medical University, Chongqing Key Laboratory of Nutrition and Food Safety, Chongqing 400038, PR China.
4
Research Center of Nutrition and Food Safety, The Third Military Medical University, Chongqing Key Laboratory of Nutrition and Food Safety, Chongqing 400038, PR China. Electronic address: zjdnfs@126.com.
5
Research Center of Nutrition and Food Safety, The Third Military Medical University, Chongqing Key Laboratory of Nutrition and Food Safety, Chongqing 400038, PR China. Electronic address: mimantian@hotmail.com.

Abstract

Ampelopsis grossedentata, a medicinal and edible plant, has been widely used in China for hundreds of years, and dihydromyricetin is the main active ingredient responsible for its various biological actions. We investigated the effects of dihydromyricetin on glucose and lipid metabolism, inflammatory mediators and several biomarkers in nonalcoholic fatty liver disease. In a double-blind clinical trial, sixty adult nonalcoholic fatty liver disease patients were randomly assigned to receive either two dihydromyricetin or two placebo capsules (150 mg) twice daily for three months. The serum levels of alanine, aspartate aminotransferase, γ-glutamyl transpeptidase, glucose, low-density lipoprotein-cholesterol and apolipoprotein B, and the homeostasis model assessment of insulin resistance (HOMA-IR) index were significantly decreased in the dihydromyricetin group compared with the placebo group. In the dihydromyricetin group, the serum levels of tumor necrosis factor-alpha, cytokeratin-18 fragment and fibroblast growth factor 21 were decreased, whereas the levels of serum adiponectin were increased at the end of the study. We conclude that dihydromyricetin supplementation improves glucose and lipid metabolism as well as various biochemical parameters in patients with nonalcoholic fatty liver disease, and the therapeutic effects of dihydromyricetin are likely attributable to improved insulin resistance and decreases in the serum levels of tumor necrosis factor-alpha, cytokeratin-18, and fibroblast growth factor 21.

KEYWORDS:

Ampelopsin (PubChem CID: 161557); Cytokeratin-18 fragment; Dihydromyricetin; Dihydromyricetin (PubChem CID: 161557); Fibroblast growth factor 21; Insulin resistance; Nonalcoholic fatty liver disease

PMID:
26032587
DOI:
10.1016/j.phrs.2015.05.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center